These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24421468)

  • 1. Continuing education case study quiz.
    Hosp Pharm; 2013 Mar; 48(3):241-2. PubMed ID: 24421468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuing education case study quiz.
    Hosp Pharm; 2013 Apr; 48(4):332-3. PubMed ID: 24421483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuing education case study quiz.
    Hosp Pharm; 2013 Feb; 48(2):153-5. PubMed ID: 24550570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuing Education Case Study Quiz.
    Hosp Pharm; 2016 Mar; 51(3):263-265. PubMed ID: 38745582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuing education case study quiz.
    Hosp Pharm; 2013 Jan; 48(1):57-9. PubMed ID: 24550569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review.
    Capone F; Motolese F; Luce T; Rossi M; Magliozzi A; Di Lazzaro V
    Mult Scler Relat Disord; 2021 Feb; 48():102734. PubMed ID: 33429305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
    Luetic G; Menichini ML; Burgos M; Alonso R; Carnero Contentti E; Carrá A; Deri N; Steinberg J; Rojas JI;
    Mult Scler Relat Disord; 2021 Aug; 53():103049. PubMed ID: 34130197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost of teriflunomide in the treatment of relapsing-remitting multiple sclerosis.
    Millar JA
    N Z Med J; 2019 Feb; 132(1490):36-41. PubMed ID: 30789887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of drug-induced bullous pemphigoid associated with teriflunomide: A patient with relapsing multiple sclerosis.
    Arslan D; Aksakal AB; Erdem Ö; Tuncer MA
    Mult Scler Relat Disord; 2020 Aug; 43():102157. PubMed ID: 32446168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
    Brunetti L; Wagner ML; Maroney M; Ryan M
    Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
    Comi G; Freedman MS; Kappos L; Olsson TP; Miller AE; Wolinsky JS; O'Connor PW; Benamor M; Dukovic D; Truffinet P; Leist TP
    Mult Scler Relat Disord; 2016 Jan; 5():97-104. PubMed ID: 26856952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
    Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update of teriflunomide for treatment of multiple sclerosis.
    Oh J; O'Connor PW
    Ther Clin Risk Manag; 2013; 9():177-90. PubMed ID: 23761970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [TERIFLUNOMIDE: A NEW ORAL IMMUNOMODULATING AGENT FOR MULTIPLE SCLEROSIS].
    Bencsik K; Rózsa C; Vécsei L
    Ideggyogy Sz; 2015 Mar; 68(3-4):79-87. PubMed ID: 26434194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.
    Papadopoulou A; Kappos L; Sprenger T
    Expert Opin Drug Saf; 2015 May; 14(5):749-59. PubMed ID: 25687236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatigue in teriflunomide-treated patients with relapsing remitting multiple sclerosis in the real-world Teri-FAST study.
    de Sèze J; Devy R; Planque E; Delabrousse-Mayoux JP; Vandhuick O; Kabir M; Gherib A
    Mult Scler Relat Disord; 2021 Jan; 47():102659. PubMed ID: 33291032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
    Miller AE
    Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.